Info@ThinkPinkRocks.com

Alkermes reports topline results from phase 2 study of ALKS 5461 drug for major depressive disorder

Alkermes plc (NASDAQ: ALKS) today announced positive preliminary topline results from a phase 2 study of ALKS 5461, its novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression.

See original article:
Alkermes reports topline results from phase 2 study of ALKS 5461 drug for major depressive disorder

Share
  1. I just want to mention I’m all new to blogging and really enjoyed this blog site. Almost certainly I’m going to bookmark your website . You definitely have exceptional article content. Thanks a lot for revealing your webpage.

  2. We liked looking over your post, it could be quite possibly the most useful overviews we have read on the topic. Basically wonderful article! I’m also an expert within this topic so I can realize your hard work.

  3. Spot on with this write-up, I actually suppose this website needs far more consideration. I’ll most likely be once more to read much more, thanks for that info.

Leave a Reply

Solve : *
29 + 16 =